The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s

Health Economics
P M DanzonLiang Wang

Abstract

We analyze the effect of price regulation on delays in launch of new drugs. Because a low price in one market may 'spill-over' to other markets, through parallel trade and external referencing, manufacturers may rationally prefer longer delay or non-launch to accepting a relatively low price. We analyze the launch in 25 major markets, including 14 EU countries, of 85 new chemical entities (NCEs) launched between 1994 and 1998. Each NCE's expected price and market size in a country are estimated using lagged average price and market size of other drugs in the same (or related) therapeutic class. We estimate a Cox proportional hazard model of launch in each country, relative to first global launch. Only 55% of the potential launches occur. The US leads with 73 launches, followed by Germany (66) and the UK (64). Only 13 NCEs are launched in Japan, 26 in Portugal and 28 in New Zealand. The results indicate that countries with lower expected prices or smaller expected market size have fewer launches and longer launch delays, controlling for per capita income and other country and firm characteristics. Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative.

Citations

Dec 23, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Livio Garattini, Simone Ghislandi
Feb 7, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Joshua CohenBrian Young
Apr 21, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Joshua Cohen
Sep 11, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Saradindu Bhaduri, Thomas Brenner
Feb 17, 2005·International Journal of Health Care Finance and Economics·Frank R Lichtenberg
Jun 20, 2006·International Journal of Health Care Finance and Economics·Y Richard Wang
Jul 2, 2008·International Journal of Health Care Finance and Economics·A H G M Spithoven
Apr 1, 2010·Pharmacy World & Science : PWS·Rajan RagupathyDavid Reith
Jun 17, 2011·Health Economics, Policy, and Law·Panos G Kanavos, Sotiris Vandoros
Oct 15, 2005·Nature Clinical Practice. Gastroenterology & Hepatology·Eamonn M M Quigley
Aug 2, 2012·Health Research Policy and Systems·Inthira Yamabhai, Richard D Smith
Jan 9, 2008·Health Affairs·Dana P GoldmanEric Sun
Dec 18, 2008·Health Affairs·Darius N LakdawallaItalo Gutierrez
Jul 16, 2008·PharmacoEconomics·Anke Richter
May 4, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Rodrigo Refoios CamejoFrans Rutten
Oct 23, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Kurt Richard BrekkeTor Helge Holmås
Jun 27, 2015·Applied Health Economics and Health Policy·Ulf Persson, Bengt Jönsson
Oct 22, 2011·Health Policy·Christine LeopoldRichard Laing
Jul 12, 2007·The Canadian Journal of Cardiology·Jacques LeLorier, Nugek S B Rawson
Apr 28, 2009·Clinical Therapeutics·Jaana E Martikainen, Hannes Enlund
Nov 19, 2015·Journal of Health Economics·Chirantan ChatterjeeViswanath Pingali
Jun 20, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Zoltán KalóPanos Kanavos
Nov 27, 2009·Clinical Pharmacology and Therapeutics·Y HiraiS Ono
Oct 3, 2012·Health Economics·Andrea Mantovani, Alireza Naghavi
Nov 19, 2011·Health Services Research·Vincenzo AtellaLorenzo Carbonari
Jun 26, 2010·Health Economics·Begoña Garcia MariñosoPau Olivella
May 1, 2009·Health Economics·Abdülkadir Civan, Bülent Köksal
May 8, 2015·Journal of Comparative Effectiveness Research·Michael R EberRobert W Dubois
Jul 26, 2015·Health Economics Review·Stephan Eger, Jörg C Mahlich
Jul 26, 2015·Health Economics Review·Ebenezer K Tetteh, Stephen Morris
Jul 22, 2014·Health Economics·Nicolas Houy, Izabela Jelovac
Jan 23, 2013·Drug Discovery Today·Alessandro RosielloFilippo Fiorini
Mar 20, 2014·Health Policy·Jaume Puig-Junoy, Beatriz González López-Valcárcel
Apr 3, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Chee-Ruey Hsieh, Frank A Sloan
Nov 1, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David B Ridley
Sep 12, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Katri AaltonenPauline Norris

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.